Page last updated: 2024-11-04

propylene glycol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Propylene Glycol: A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

propane-1,2-diol : The simplest member of the class of propane-1,2-diols, consisting of propane in which a hydrogen at position 1 and a hydrogen at position 2 are substituted by hydroxy groups. A colourless, viscous, hygroscopic, low-melting (-59degreeC) and high-boiling (188degreeC) liquid with low toxicity, it is used as a solvent, emulsifying agent, and antifreeze. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1030
CHEMBL ID286398
CHEBI ID16997
MeSH IDM0029618

Synonyms (250)

Synonym
2,3-propanediol
ch3ch(oh)ch2oh
hoch2ch(oh)me
mech(oh)ch2oh
CHEBI:16997 ,
1,2-propylenglykol
alpha-propyleneglycol
hoch2ch(oh)ch3
isopropylene glycol
s-(+)-propylene glycol
nsc-35748
nsc35747
nsc35748
nsc-35747
nsc-35749
nsc35749
pg 12
nsc69860
trimethyl glycol
methylethylene glycol
methylethyl glycol
.alpha.-propylene glycol
wln: qy1&1q
2-hydroxypropanol
1,2-propylene glycol
1,2-dihydroxypropane
sirlene
monopropylene glycol
nsc-69860
propylene glycol (tn)
D00078
propylene glycol (jp17/usp)
sdm no. 27
nsc 69860
1,2-propylenglykol [german]
LS-1391 ,
einecs 200-338-0
brn 1340498
(+-)-propylene glycol
propylene glycol usp
solar winter ban
fema no. 2940
solargard p
sentry propylene glycol
ccris 5929
epa pesticide chemical code 068603
1,2-propanediol (8ci,9ci)
(+-)-1,2-propanediol
(rs)-1,2-propanediol
dl-1,2-propanediol
ai3-01898
alpha-propylene glycol
caswell no. 713
1,2-(rs)-propanediol
dl-propylene glycol
hsdb 174
1,2-propane-diol
ucar 35
1000pg
dowfrost
l-1,2-propanediol
NCGC00090739-01
NCGC00090739-02
57-55-6
1,2-propanediol
C00583
propane-1,2-diol
methyl glycol
propylene glycol
propylene glycol, fcc, fg
propylene glycol, meets usp testing specifications
DB01839
1,2-propanediol, acs reagent, >=99.5%
1,2-propanediol, reagentplus(r), 99%
smr000677948
MLS001055394
glycol, propylene
1,2 propanediol
propan-1,2-diol
1,2-propanediol, puriss. p.a., acs reagent, >=99.5% (gc)
1,2-propanediol, meets analytical specification of ph. eur., bp, usp, >=99.5%
propylene glycol cefatrizine
kollisolv pg
kilfrost abc-s
e1520
e490
propyleneglycolum
CHEMBL286398
propylene glycol dl-form
ins no.1520
propylene glycol (solvent)
e-1520 ,
ins-1520
BMSE000302
63625-56-9
AKOS000121049
NCGC00090739-03
NCGC00090739-04
propylenglycol
1,2-propane diol
HMS3039O11
tox21_301441
dsstox_gsid_27863
dsstox_rid_78594
cas-25322-69-4
NCGC00255183-01
dsstox_cid_1206
NCGC00259361-01
tox21_300006
tox21_201812
NCGC00254159-01
BBL011472
P0485
123120-98-9
cas-57-55-6
dtxsid0021206 ,
dtxcid901206
tox21_111003
STL146584
unii-6dc9q167v3
all purpose lubricant
general lube
6dc9q167v3 ,
ec 200-338-0
3-01-00-02142 (beilstein handbook reference)
propylene glycol [usp:jan]
FT-0605030
FT-0606483
FT-0605236
EPITOPE ID:161748
AKOS016355793
BP-21014
propylene glycol [usp-rs]
propylene glycol [usp monograph]
propylene glycol dl-form [mi]
propylene glycol [ep monograph]
propylene glycol [jan]
propyleneglycolum [who-ip latin]
propanediol-
propylene glycol [ii]
propylene glycol [inci]
propylene glycol [mart.]
propylene glycol (solvent) [vandf]
(+/-)-1,2-propanediol
glycerol impurity c [ep impurity]
propylene glycol [vandf]
propylene glycol [fhfi]
(2rs)-propane-1,2-diol
propylene glycol [mi]
propylene glycerol
propylene glycol [who-dd]
propylene glycol [hsdb]
propylene glycol [fcc]
propylene glycol [who-ip]
mfcd00066248
SY003769
SY003770
J-502273
1,2-propyleneglycol
propylene-glycol
racemic propylene glycol
1,2 -propanediol
1,2-propandiol
1.2-propanediol
racemic 1,2-propanediol
ilexan p
(.+/-.)-1,2-propanediol
prolugen
propylene glycol, british pharmacopoeia (bp) reference standard
mfcd00064272
F1908-0071
1,2-propanediol, tested according to ph.eur.
1,2-propanediol, acs reagent
1,2-propanediol, analytical reference material
propylene glycol, united states pharmacopeia (usp) reference standard
1,2-propanediol, saj first grade, >=99.0%
1,2-propanediol, reagentplus(r), >=99%
1,2-propanediol, analytical standard
1,2-propanediol, saj special grade, >=99.0%
1,2-propanediol, puriss., 99.5%
1,2-propanediol, vetec(tm) reagent grade, 98%
1,2-propanediol, usp, 99.5%
propylene glycol, european pharmacopoeia (ep) reference standard
propylene glycol, pharmaceutical secondary standard; certified reference material
1,2-propanediol, p.a., acs reagent, 99.5%
1,2-propanediol, lr, >=99%
propylene glycol (propane-1,2-diol)
propylene glycol; (rs)-propane-1,2-diol; glycerol imp. c (ep); gr 43314x; glycerol impurity c
CS-0015917
HY-Y0921
( inverted exclamation marka)-1,2-propanediol
1,2-propanediol 100 microg/ml in acetonitrile
BCP23677
Q161495
1,2-pdo
1,2-(rs)-propanediol; 1,2-dihydroxypropane; 1,2-propylene glycol
poly(propylene glycol) average mn 400
S6258
SB44656
SB44657
()-1,2-propanediol
CRB71005
1-2-propanediol
EN300-21726
poly(propylene glycol) average mn 4000
poly(propylene glycol) average mn 2000
lubricant eye drops restorative performance
restorative formula lubricant eye drops
ob lube
propylenglycolum
propylene glycol (ii)
general ob lubricant
glikol propylenowy
propyleeniglykoli
equate lubricant eye drops restorative performance
propylene glycol (mart.)
non spermicidal sterile lubricating jelly
metiletilenglicol
eyelash and eyebrow lengthener
keto-treat
propylenglykol
propylene glycol (usp:jan)
glycerol impurity c (ep impurity)
systane balance
propylene glycol (usp-rs)
1,2-hydroxypropane
propylene glycol (ep monograph)
vet lube
cvs health lubricant drops
glicol propilenico
2-dihydroxypropanol
propilenoglicol
walgreens complete lubricant eye drops
sirlene /former use/
equate support moisture lubricant eye
propane-1,2-glycol
sterile lubricant drops
systane complete pf
heb lubricant eye drops dry eye therapy
propylene glycol (usp monograph)
cvs lubricant eye drops 15ml
gr12
lubiseptol lubricant
usepa/opp pesticide code: 068603
derofen miel
systane complete
walgreens lubricant eye drops restorative performance
propylene glycol u.s.p.
walgreen sterile lubricant
Z106938868

Research Excerpts

Overview

Propylene glycol (PG) is a well-documented causative agent of allergic contact dermatitis (ACD) It is a commonly used diluent in several pharmaceutical preparations, including the sedative lorazepam. PG is a precursor of ruminal propionate, and feeding PG has been reported to improve energy supply by increasing blood glucose.

ExcerptReferenceRelevance
"Propylene glycol (PG) is a solvent, vehicle, and humectant being used increasingly in a wide array of personal care products, cosmetics, and topical medicaments. "( Patch Testing to Propylene Glycol: The Mayo Clinic Experience.
Chaudhry, H; Davis, MDP; Drage, LA; Hall, MR; Killian, JM; Lalla, SC; Nguyen, H; Yiannias, JA,
)
1.91
"Propylene glycol is a rarely reported toxicity from high-dose administration of certain intravenous drugs, including lorazepam and pentobarbital. "( Iatrogenic Propylene Glycol Intoxication Due to High-Dose Pentobarbital for Refractory Intracranial Hypertension: A Case Report.
Barthol, CA; Garvin, RE; Rios, D; Smedley, LW, 2020
)
2.39
"Propylene glycol (PG) is a main component in several commercial formulations of ADFs."( Natural and enhanced biodegradation of propylene glycol in airport soil.
Anton, A; Biró, B; Colarieti, ML; Greco, G; Toscano, G, 2014
)
1.39
"Propylene glycol is a well-documented causative agent of allergic contact dermatitis (ACD). "( Excipients in Oral Antihistamines Can Perpetuate Allergic Contact Dermatitis.
Belazarian, L; Foley, E; Robinson, A; Silvestri, DL; Tocci, EM; Wiss, K,
)
1.57
"Propylene glycol is a commonly used diluent in several pharmaceutical preparations, including the sedative lorazepam. "( A prospective evaluation of propylene glycol clearance and accumulation during continuous-infusion lorazepam in critically ill patients.
Forrest, A; Haas, CE; Habtemariam, B; Kaufman, DC; Nelsen, JL; Partridge, A; Welle, S,
)
1.87
"Propylene glycol (PG) is a precursor of ruminal propionate, and feeding PG has been reported to improve energy supply by increasing blood glucose."( Effects of peripartum propylene glycol supplementation on nitrogen metabolism, body composition, and gene expression for the major protein degradation pathways in skeletal muscle in dairy cows.
Chibisa, GE; Gozho, GN; Mutsvangwa, T; Olkowski, AA; Van Kessel, AG, 2008
)
1.38
"Propylene glycol (PG) is a humectant commonly used in cigarettes. "( Toxicological considerations on the use of propylene glycol as a humectant in cigarettes.
Coggins, CR; Gaworski, CL; Oldham, MJ, 2010
)
2.07
"Propylene glycol is a diluent found in many intravenous and oral drugs, including phenytoin, diazepam, and lorazepam. "( Severe lactic acidosis after an iatrogenic propylene glycol overdose.
Egelhoff, E; Heard, K; Zosel, A, 2010
)
2.07
"Propylene glycol (PG) is an unintentional frequently administered solvent in neonates despite the fact that PG accumulation potentially results in hyperosmolarity, lactic acidosis and renal/hepatic toxicity."( Prospective assessment of short-term propylene glycol tolerance in neonates.
Allegaert, K; Cosaert, K; de Hoon, J; Debeer, A; Kulo, A; Vanhaesebrouck, S; Verbesselt, R, 2010
)
2.08
"Propylene glycol (PG) is a common solvent used in medical preparations. "( Propylene glycol produces excessive apoptosis in the developing mouse brain, alone and in combination with phenobarbital.
Farber, NB; Lau, K; Noguchi, KK; Reeves, N; Swiney, BS, 2012
)
3.26
"Propylene glycol is an aliphatic alcohol that functions as a skin conditioning agent, viscosity decreasing agent, solvent, and fragrance ingredient in cosmetics. "( Safety assessment of propylene glycol, tripropylene glycol, and PPGs as used in cosmetics.
Andersen, FA; Belsito, DV; Bergfeld, WF; Fiume, MM; Hill, RA; Klaassen, CD; Liebler, D; Marks, JG; Shank, RC; Slaga, TJ; Snyder, PW,
)
1.89
"Propylene glycol (PG) is a main component of aircraft deicing fluids and its extensive use in Northern airports is a source of soil and groundwater contamination. "( Aerobic biodegradation of propylene glycol by soil bacteria.
Andreoni, V; Cavalca, L; Ciccazzo, S; Greco, G; Letizia Colarieti, M; Rao, MA; Scelza, R; Scotti, R; Toscano, G, 2013
)
2.13
"Propylene glycol toxicity is a potentially life-threatening iatrogenic complication that is common and preventable. "( Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and prospective, observational pilot study.
Farber, HW; Reardon, C; Theodore, AC; Wilson, KC, 2005
)
3.21
"Propylene glycol is a commonly used solvent for oral, intravenous, and topical pharmaceutical preparations. "( Recognition, treatment, and prevention of propylene glycol toxicity.
Graeber, C; Perazella, MA; Zar, T,
)
1.84
"Propylene glycol is an excipient of various pharmaceutical preparations. "( Pharmacokinetics of propylene glycol after rectal administration.
Goldhoorn, PB; Kollöffel, WJ; Weekers, LE, 1996
)
2.06
"Propylene glycol is a solvent that is used in many oral, injectable, and topical medications. "( Propylene glycol-induced proximal renal tubular cell injury.
Al-Uzri, A; Boyer-Hassen, LV; Davenport, K; Johnson, MI; Theodorou, AA; Yorgin, PD, 1997
)
3.18
"Propylene glycol is a common solvent often contained in injectable solutions of anxiolytics of low water-solubility, such as diazepam (Valium) and pentobarbital (Nembutal). "( Propylene glycol elicits anxiolytic-like responses to the elevated plus-maze in male mice.
Burden, PM; Johnston, GA; Lin, HQ, 1998
)
3.19
"Propylene glycol (PG) is a widely used vehicle for water-insoluble drugs. "( Osmolalities of propylene glycol-containing drug formulations for parenteral use. Should propylene glycol be used as a solvent?
Doenicke, A; Hoernecke, R; Mayer, M; Nebauer, AE; Roizen, MF, 1992
)
2.07
"Propylene glycol (PG) is a common preservative and source of synthetic carbohydrates in soft-moist pet foods. "( Contribution of propylene glycol-induced Heinz body formation to anemia in cats.
Christopher, MM; Eaton, JW; Perman, V, 1989
)
2.07

Effects

Propylene glycol (PG) has a long history of use as a component of topical pharmaceutical and cosmetic preparations. It has a lower evaporation rate than water, providing an even more stringent test for surface tension effects in late ESI droplets.

Propylene glycol (PG) has been used in formulations as a co-solvent and/or to enhance drug permeation through the skin from topical preparations. It has been proved effective in the treatment of pityriasis versicolor, Pityrosporon folliculitis, and seborrheic dermatitis.

ExcerptReferenceRelevance
"Propylene glycol (PG) has a long history of use as a component of topical pharmaceutical and cosmetic preparations."( Optimisation of cosolvent concentration for topical drug delivery - II: influence of propylene glycol on ibuprofen permeation.
Guy, RH; Hadgraft, J; Lane, ME; Watkinson, RM, 2009
)
1.3
"Propylene glycol also has a lower evaporation rate than water, providing an even more stringent test for surface tension effects in late ESI droplets."( Protein charge-state distributions in electrospray-ionization mass spectrometry do not appear to be limited by the surface tension of the solvent.
Grandori, R; Samalikova, M, 2003
)
1.04
"Propylene glycol (PG) has an excitatory effect on the skeletal muscle of the frog. "( Facilitation of mouse neuromuscular transmission by propylene glycol.
Hattori, T; Maehashi, H, 1995
)
1.98
"Propylene glycol (PG) has widespread use in pharmaceuticals, cosmetics, fragrances and personal care products. "( Propylene glycol, skin sensitisation and allergic contact dermatitis: A scientific and regulatory conundrum.
Kimber, I; Pemberton, MA, 2023
)
3.8
"Propylene glycol (PG) has been used in formulations as a co-solvent and/or to enhance drug permeation through the skin from topical preparations. "( Effect of propylene glycol on the skin penetration of drugs.
Alonso, C; Barba, C; Carrer, V; Coderch, L; Córdoba, M; Espinosa, S; Martí, M; Oliver, MA; Pont, M; Zanuy, M, 2020
)
2.4
"Propylene glycol (PG) has been selected as gelling agent because it ensures homogenous gelation in relatively short times (from few minutes up to 6 h)."( Development of injectable and durable kefiran hydro-alcoholic gels.
Carfì Pavia, F; Dispenza, C; Ghersi, G; Giacomazza, D; La Carrubba, V; Rigogliuso, S; Sabatino, MA, 2020
)
1.28
"Propylene glycol (PG) has a long history of use as a component of topical pharmaceutical and cosmetic preparations."( Optimisation of cosolvent concentration for topical drug delivery - II: influence of propylene glycol on ibuprofen permeation.
Guy, RH; Hadgraft, J; Lane, ME; Watkinson, RM, 2009
)
1.3
"Propylene glycol also has a lower evaporation rate than water, providing an even more stringent test for surface tension effects in late ESI droplets."( Protein charge-state distributions in electrospray-ionization mass spectrometry do not appear to be limited by the surface tension of the solvent.
Grandori, R; Samalikova, M, 2003
)
1.04
"Propylene glycol (PG) has an excitatory effect on the skeletal muscle of the frog. "( Facilitation of mouse neuromuscular transmission by propylene glycol.
Hattori, T; Maehashi, H, 1995
)
1.98
"Propylene glycol has been proved effective in the treatment of pityriasis versicolor, Pityrosporon folliculitis, and seborrheic dermatitis."( Short-term treatment of dandruff with a combination of propylene glycol solution and shampoo.
Faergemann, J, 1988
)
1.24

Actions

Propylene glycol (PG) may cause allergic or irritant contact dermatitis. PG also has a lower evaporation rate than water, providing an even more stringent test for surface tension effects.

ExcerptReferenceRelevance
"Propylene glycol was found to increase mupirocin loading, whereas polyethylene glycol 400 showed no effect."( Effect of solubilizing agents on mupirocin loading into and release from PEGylated nanoliposomes.
Barenholz, Y; Cern, A; Goldblum, A; Nativ-Roth, E, 2014
)
1.12
"Propylene glycol (PG) may cause allergic or irritant contact dermatitis. "( Positive patch-test reactions to propylene glycol: a retrospective cross-sectional analysis from the North American Contact Dermatitis Group, 1996 to 2006.
Belsito, DV; Botto, NC; DeLeo, VA; Fowler, JF; Maibach, HI; Marks, JG; Mathias, CG; Pratt, MD; Rietschel, RL; Sasseville, D; Storrs, FJ; Taylor, JS; Warshaw, EM; Zug, KA,
)
1.86
"Propylene glycol also has a lower evaporation rate than water, providing an even more stringent test for surface tension effects in late ESI droplets."( Protein charge-state distributions in electrospray-ionization mass spectrometry do not appear to be limited by the surface tension of the solvent.
Grandori, R; Samalikova, M, 2003
)
1.04
"Propylene glycol may cause contact allergy, but there is sparse information on health effects from occupational exposure to PG."( Experimental exposure to propylene glycol mist in aviation emergency training: acute ocular and respiratory effects.
Lindgren, T; Norbäck, D; Wieslander, G, 2001
)
1.34

Treatment

ExcerptReferenceRelevance
"Pretreatment with propylene glycol (5 microliters/g b.wt., twice with a 60-min interval), a selective CYP2E1 inhibitor, reduced the increase in the tail length by about half at all doses in both cell types (p < 0.01)."( Benzene-induced genotoxicity in mice in vivo detected by the alkaline comet assay: reduction by CYP2E1 inhibition.
Loft, S; Poulsen, HE; Thomsen, MS; Tuo, J, 1996
)
0.62

Toxicity

The Expert Panel concluded that PG, tripropylene glycol, and PPGs ≥3 are safe as used in cosmetic formulations when formulated to be nonirritating. The poloxamer-based solid suppository system with clotrimazole/P 188 was an effective rectal dosage form.

ExcerptReferenceRelevance
" Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment."( Chronic carbamazepine treatment in the rat: efficacy, toxicity, and effect on plasma and tissue folate concentrations.
Carl, GF; Smith, ML,
)
0.13
" The LD50 associated with seizure activity was lower in mice receiving MMT in propylene glycol (152 mg/kg) than in those receiving MMT in corn oil (999 mg/kg)."( Neurotoxic effects of methylcyclopentadienyl manganese tricarbonyl (MMT) in the mouse: basis of MMT-induced seizure activity.
Fishman, BE; Gianutsos, G; McGinley, PA, 1987
)
0.5
" We believed that this represented an adverse effect that was probably related to the study drug and the study was stopped."( Propylene glycol toxicity following continuous etomidate infusion for the control of refractory cerebral edema.
Aranda, M; Giannotta, SL; Levy, ML; Zelman, V, 1995
)
1.73
" These toxic effects reached an apparent maximum within 2 hr."( Acute toxicity of propylene glycol: an assessment using cultured proximal tubule cells of human origin.
Jain, SK; McMartin, KE; Morshed, KM, 1994
)
0.62
" Although considered to be a relatively safe substance, overdoses have been associated with serious adverse effects."( Propylene glycol: the safe diluent that continues to cause harm.
Glover, ML; Reed, MD,
)
1.57
"Streams receiving runoff from General Mitchell International Airport (GMIA), Milwaukee, Wisconsin, USA, were studied to assess toxic impacts of aircraft and runway deicers."( Aircraft and runway deicers at General Mitchell International Airport, Milwaukee, Wisconsin, USA. 2. Toxicity of aircraft and runway deicers.
Corsi, SR; Geis, SW; Hall, DW, 2001
)
0.31
" This study aimed to select the least toxic among the cryoprotectants dimethyl sulfoxide (Me2SO), propylene glycol (PG), and methanol (MET) based on their toxicological effects on Crassostrea rhizophorae gametes and trochophores."( Selection of cryoprotectants based on their toxic effects on oyster gametes and embryos.
do Espírito Santo, EM; Leite, MB; Nascimento, IA; Pereira, SA; Sampaio de Araújo, MM; Sansone, G, 2005
)
0.55
" Thus, the poloxamer-based solid suppository system with clotrimazole/P 188/propylene glycol was an effective rectal dosage form for the treatment of tumors with alleviated adverse effects."( Enhanced anti-tumor activity and alleviated hepatotoxicity of clotrimazole-loaded suppository using poloxamer-propylene glycol gel.
Choi, HG; Kim, JA; Lee, MH; Oh, YK; Paek, SH; Woo, JS; Xuan, JJ; Yong, CS, 2006
)
0.78
" The histopathological analysis indicates the absence of inflammation on administration, suggesting that these formulations are safe during the studied period."( Biodegradable in situ gelling system for subcutaneous administration of ellagic acid and ellagic acid loaded nanoparticles: evaluation of their antioxidant potential against cyclosporine induced nephrotoxicity in rats.
Italia, JL; Ravi Kumar, MN; Sharma, G; Sonaje, K; Tikoo, K, 2007
)
0.34
" Severe adverse effects have been noted with pharmaceutical formulations containing diethylene glycol monoethyl-ethers and this led to withdrawal from the French market."( [Hormone replacement therapy: toxicity of glycol ethers].
Biggi-Bernard, U; Descotes, J; Timour, Q, 2007
)
0.34
" Toxic effects include hyperosmolality, increased anion gap metabolic acidosis (due to lactic acidosis), acute kidney injury, and sepsis-like syndrome."( Recognition, treatment, and prevention of propylene glycol toxicity.
Graeber, C; Perazella, MA; Zar, T,
)
0.4
" Previous studies demonstrated differential expression of hepatobiliary transporter mRNA in mice treated with a toxic dose of APAP dissolved in 50% propylene glycol."( Influence of acetaminophen vehicle on regulation of transporter gene expression during hepatotoxicity.
Aleksunes, LM; Augustine, LM; Cherrington, NJ; Manautou, JE, 2007
)
0.54
" This study aimed to identify possible toxic mechanisms using primary cell cultures from vascular tissue: these were exposed to the cryoprotectant at room temperature to avoid any possibility of hypothermic injury."( Reduction of cryoprotectant toxicity in cells in suspension by use of a sodium-free vehicle solution.
Hunds, N; Pegg, DE; Rauen, U; Simmonds, J; Wusteman, M, 2008
)
0.35
"To determine a threshold dose for parenteral lorazepam when screening for propylene glycol toxicity with the osmol gap, and to characterize which osmol gap values are more predictive of toxic propylene glycol concentrations and resultant clinical toxicity."( Determination of a lorazepam dose threshold for using the osmol gap to monitor for propylene glycol toxicity.
Fraser, GL; Riker, RR; Subak-Sharpe, S; Yahwak, JA, 2008
)
0.8
" Unfortunately cryoprotectants can be toxic for cells."( Studies on cryoprotectant toxicity to early stage zebrafish (Danio rerio) ovarian follicles.
Rawson, DM; Tsai, S; Zhang, T,
)
0.13
" First convincingly introduced by Baxter and Lathe in 1971, the concept that certain amides can block toxic effects of dimethyl sulfoxide (Me(2)SO) was contradicted by direct experiments in 1990."( Cryoprotectant toxicity neutralization.
Fahy, GM, 2010
)
0.36
"Vitrification requires high concentrations of cryoprotectants that may induce long-term toxic effects on cells."( Assessment of the genotoxicity of three cryoprotectants used for human oocyte vitrification: dimethyl sulfoxide, ethylene glycol and propylene glycol.
Aye, M; Botta, A; Courbiere, B; De Mo, M; Di Giorgio, C; Perrin, J, 2010
)
0.56
" These substances are sorted according to their toxic effect and new excipients not yet used in the respiratory tract like HPMC can be classified in this scheme."( The MTT assay as tool to evaluate and compare excipient toxicity in vitro on respiratory epithelial cells.
Scherliess, R, 2011
)
0.37
" In addition, the potential for persistence or reversibility of any toxic effects were assessed after a 6-week recovery period."( Safety and toxicology of cyclosporine in propylene glycol after 9-month aerosol exposure to beagle dogs.
Briscoe, C; Gibbs, S; Lynch, M; Moutvic, R; Niven, R; Raff, H, 2011
)
0.64
"Multiple-CPA solutions were significantly less toxic than single-CPA solutions (P<0."( Cryoprotective agent toxicity interactions in human articular chondrocytes.
Almansoori, KA; Elliott, JA; Forbes, JF; Jomha, NM; Law, GK; McGann, LE; Prasad, V, 2012
)
0.38
" PG was the most toxic CPA when used in combinations."( Cryoprotective agent toxicity interactions in human articular chondrocytes.
Almansoori, KA; Elliott, JA; Forbes, JF; Jomha, NM; Law, GK; McGann, LE; Prasad, V, 2012
)
0.38
"The objective of the present work was to evaluate the broadest toxic effect of some synthetic additives of colorants and/or flavors on different body organs and metabolic aspects in rats."( Toxic effects of some synthetic food colorants and/or flavor additives on male rats.
El-Wahab, HM; Moram, GS, 2013
)
0.39
" The Expert Panel concluded that PG, tripropylene glycol, and PPGs ≥3 are safe as used in cosmetic formulations when formulated to be nonirritating."( Safety assessment of propylene glycol, tripropylene glycol, and PPGs as used in cosmetics.
Andersen, FA; Belsito, DV; Bergfeld, WF; Fiume, MM; Hill, RA; Klaassen, CD; Liebler, D; Marks, JG; Shank, RC; Slaga, TJ; Snyder, PW,
)
0.72
"The aim of the present study was to determine whether applying obstetric gel, a noninvasive method of pain management that is safe both for the mother and the child, during labor influences delivery satisfaction by facilitating pain management and decreasing exhaustion."( Searching for Medical Substances Safe for Mother and Child, Facilitating the Delivery of Pain Management and Decreasing Exhaustion--Evaluation of Obstetric Gel by Pregnant Women.
Kwasniewska, A; Makara-Studzinska, M; Rolinska, AA; Tomasz, G, 2015
)
0.42
" The aim of sharing these data, including adverse findings, is to provide meaningful information for vehicle selection, thereby avoiding repetition of animal experimentation."( Safety data on 19 vehicles for use in 1 month oral rodent pre-clinical studies: administration of hydroxypropyl-ß-cyclodextrin causes renal toxicity.
Burdett, L; Cotton, P; Finney, R; Garner, C; Hargreaves, A; Harris, J; Healing, G; Kirk, S; Pivette, P; Schramm, C; Sulemann, T, 2016
)
0.43
" The incidence of grade 3 mucositis and stomatitis was low (10% and 5%, respectively) with no grade 4 mucositis or stomatitis reported (graded according to National Cancer Institute Common Terminology Criteria for Adverse Events)."( A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
Aljitawi, OS; Allen, LF; Arce-Lara, C; Bhat, G; Callander, N; Hari, P; Nath, R; Stockerl-Goldstein, K, 2015
)
0.64
" The most frequently reported adverse event was eye irritation (HPG/PEG/PG, n=2; O/CMC, n=3)."( Safety and efficacy of a hydroxypropyl guar/polyethylene glycol/propylene glycol-based lubricant eye-drop in patients with dry eye.
Baudouin, C; Labetoulle, M; Messmer, EM; Ogundele, A; Pisella, PJ, 2017
)
0.69
" Calls to poison control centers about e-cigarette toxicity, especially in children, and case reports of toxic exposures have increased over the past 3 years."( Electronic Cigarette Toxicity.
Michaels, D; Nugent, K; Orellana-Barrios, M; Payne, JD, 2017
)
0.46
" coli mutant screening approach, which indicated that BMP has a distinct mode of toxic action."( Functional genomic assessment of 2, 2-bis (bromomethyl)-1, 3-propanediol induced cytotoxicity in a single-gene knockout library of E. coli.
Guan, M; Zhang, X, 2017
)
0.46
"890 mg VG/L) were observed, and no adverse effects for PG/VG/nicotine were observed up to 438/544/6."( Toxicity of the main electronic cigarette components, propylene glycol, glycerin, and nicotine, in Sprague-Dawley rats in a 90-day OECD inhalation study complemented by molecular endpoints.
Elamin, A; Esposito, M; Guedj, E; Ho, J; Hoeng, J; Ivanov, NV; Kogel, U; Krishnan, S; Lebrun, S; Leroy, P; Martin, F; Nury, C; Peitsch, MC; Phillips, B; Schlage, WK; Sciuscio, D; Sharma, D; Titz, B; Vanscheeuwijck, P; Veljkovic, E; Vuillaume, G; Xiang, Y, 2017
)
0.7
" Our data demonstrated that the PG/VG vehicle adversely affected cell viability and that a large number of e-liquids were more toxic than PG/VG."( Evaluation of e-liquid toxicity using an open-source high-throughput screening assay.
Davis, ES; Glish, GL; Keating, JE; Kochar, TK; Sassano, MF; Tarran, R; Wolfgang, MC; Zorn, BT, 2018
)
0.48
"According to these results, SEDDS and cationic surfactants seem to bear an additive up to synergistic toxic risk."( Self-emulsifying drug delivery systems and cationic surfactants: do they potentiate each other in cytotoxicity?
Bernkop-Schnürch, A; Lam, HT; Le-Vinh, B; Phan, TNQ, 2019
)
0.51
" Although considered bioequivalent, there remains limited literature directly evaluating the adverse events between the two agents."( Evaluating the adverse effects of melphalan formulations.
Glotzbecker, B; Laubach, J; McDonnell, AM; Ni, J; Soiffer, R; Xiang, E, 2019
)
0.51
" These data may assist in better understanding the anticipated adverse effects of a high-dose melphalan conditioning therapy."( Evaluating the adverse effects of melphalan formulations.
Glotzbecker, B; Laubach, J; McDonnell, AM; Ni, J; Soiffer, R; Xiang, E, 2019
)
0.51
" Treatment-emergent adverse events (TEAEs) were reported for 88 (64."( Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1).
Cha, A; Gower, R; Lynde, C; Ports, WC; Purohit, V; Schlessinger, J; Shepard, JS; Su, JC; Takiya, L; Vlahos, B; Werth, JL; Zang, C, 2020
)
0.56
" Fewer than 1 in 25 patients experienced each side effect where crisaborole was applied."( Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1).
Cha, A; Gower, R; Lynde, C; Ports, WC; Purohit, V; Schlessinger, J; Shepard, JS; Su, JC; Takiya, L; Vlahos, B; Werth, JL; Zang, C, 2020
)
0.56
"Most flavors used in e-liquids are generally recognized as safe for oral consumption, but their potential effects when inhaled are not well characterized."( Assessment of inhalation toxicity of cigarette smoke and aerosols from flavor mixtures: 5-week study in A/J mice.
Ashutosh, K; Cammack, L; Chia, C; Chua, CS; Corciulo, M; Diana, P; Glabasnia, A; Hoeng, J; Ivanov, N; Lee, KM; Leroy, P; Luettich, K; Merg, C; Moine, F; Peitsch, M; Piault, R; Sciuscio, D; Smith, C; Tung, CK; Vanscheeuwijck, P; Wong, ET, 2022
)
0.72
"Some pharmaceutical excipients may cause adverse reactions, excipient-related interactions and/or contraindications."( Pharmaceutical excipients with potential to cause adverse effects in paediatric nasal medicines.
Canji-Panic, JM; Komazec, ZS; Lalic-Popovic, MN; Stjepanovic, AN; Tesic, TZ; Todorovic, NB, 2022
)
0.72

Pharmacokinetics

Fifty critically ill patients receiving continuous-infusion lorazepam for a minimum of 36 hours were prospectively evaluated to determine the extent of propylene glycol accumulation over time. The aim was to develop a pharmacokinetic model that would predict clearance based on patient-specific clinical, laboratory and demographic factors.

ExcerptReferenceRelevance
" In this pharmacokinetic and safety study, melatonin in propylene glycol was evaluated in adult male Sprague-Dawley rats."( Preclinical evaluation of pharmacokinetics and safety of melatonin in propylene glycol for intravenous administration.
Chan, PS; Cheung, RT; Ma, ES; Tam, S; Tipoe, GL; Zou, LY, 2006
)
0.81
" Fifty critically ill patients receiving continuous-infusion lorazepam for a minimum of 36 hours were prospectively evaluated to determine the extent of propylene glycol accumulation over time, characterize propylene glycol clearance in the presence of critical illness, and develop a pharmacokinetic model that would predict clearance based on patient-specific clinical, laboratory, and demographic factors."( A prospective evaluation of propylene glycol clearance and accumulation during continuous-infusion lorazepam in critically ill patients.
Forrest, A; Haas, CE; Habtemariam, B; Kaufman, DC; Nelsen, JL; Partridge, A; Welle, S,
)
0.62
" International Congress on Harmonization (ICH) Guidelines were followed, which recommend preliminary non-clinical safety studies using the vehicle and device (CAG-PG) prior to the first human exposure including safety pharmacology, pharmacokinetic (PK) studies, single dose toxicity studies, and repeated dose toxicity studies in two species."( Non-clinical safety and pharmacokinetic evaluations of propylene glycol aerosol in Sprague-Dawley rats and Beagle dogs.
Byron, P; Kirkpatrick, D; Lilly, P; McDonald, P; Venitz, J; Wallery, J; Werley, MS, 2011
)
0.62
"ICA-PG-liposomes changed the pharmacokinetic behaviour and enhanced icariin distribution in tissues."( Pharmacokinetics and tissue distribution profile of icariin propylene glycol-liposome intraperitoneal injection in mice.
Chen, XY; Lu, CT; Yang, W; Yu, XC; Zhang, L; Zhao, YZ, 2012
)
0.62
"A pharmacokinetic model was developed for PG co-administered with paracetamol or phenobarbital in neonates."( Developmental pharmacokinetics of propylene glycol in preterm and term neonates.
Allegaert, K; Danhof, M; De Cock, RF; de Hoon, J; Knibbe, CA; Kulo, A; Verbesselt, R, 2013
)
0.67
" According to the permeability and affinity, 7a and 9b were selected in the pharmacokinetic studies in rats."( Propylene glycol-linked amino acid/dipeptide diester prodrugs of oleanolic acid for PepT1-mediated transport: synthesis, intestinal permeability, and pharmacokinetics.
Cao, F; Fang, L; Gao, Y; Ping, Q; Wang, M, 2013
)
1.83
" The pharmacokinetic parameters were studied and recorded on animals."( Development of matrix-type transdermal delivery of lornoxicam: in vitro evaluation and pharmacodynamic and pharmacokinetic studies in albino rats.
Baviskar, DT; Jain, DJ; Parik, VB,
)
0.13
" The formulations showing best results (A3 and B3) were selected further for in vivo and pharmacokinetic studies on animals."( Development of matrix-type transdermal delivery of lornoxicam: in vitro evaluation and pharmacodynamic and pharmacokinetic studies in albino rats.
Baviskar, DT; Jain, DJ; Parik, VB,
)
0.13
" Modern high-throughput small molecule drug discovery requires rapid screening of the pharmacokinetic parameters of multiple candidate molecules in parallel."( Solvent-based formulations for intravenous mouse pharmacokinetic studies: tolerability and recommended solvent dose limits.
Bowman, T; Dean, B; Messick, K; Sambrone, A; Schweiger, M; Thackaberry, EA; Valle, N; Wang, X; Xie, M, 2014
)
0.4
" One participant had Tmax of 30 minutes."( Nicotine delivery, retention and pharmacokinetics from various electronic cigarettes.
Benowitz, NL; Dempsey, DA; Havel, C; Jacob, P; St Helen, G, 2016
)
0.43
" Although the average maximum plasma nicotine concentration in experienced e-cigarette users appears to be generally lower than what has been reported from tobacco cigarette use, the shape of the pharmacokinetic curve is similar, suggesting addictive potential."( Nicotine delivery, retention and pharmacokinetics from various electronic cigarettes.
Benowitz, NL; Dempsey, DA; Havel, C; Jacob, P; St Helen, G, 2016
)
0.43
"5 h according to the pharmacokinetic studies."( Rapid-Onset Sildenafil Sublingual Drug Delivery Systems: In Vitro Evaluation and In Vivo Pharmacokinetic Studies in Rabbits.
Chen, RN; Chou, PY; Ho, HO; Hsieh, CM; Sheu, MT, 2016
)
0.43
" Plasma levels of PG were estimated using a one-compartment pharmacokinetic model."( Assessing Propylene Glycol Toxicity in Alcohol Withdrawal Patients Receiving Intravenous Benzodiazepines: A One-Compartment Pharmacokinetic Model.
Bodreau, C; Elbarbry, F; Farthing, K; Jahn, A, 2018
)
0.88

Compound-Compound Interactions

ExcerptReferenceRelevance
" This megazol gel, when used in combination with melarsoprol (3."( Topical chemotherapy for experimental African trypanosomiasis with cerebral involvement: the use of melarsoprol combined with the 5-nitroimidazole, megazol.
Chauvière, G; Jennings, FW; Murray, M; Viode, C, 1996
)
0.29
" As a result, this study used intrabony defects to evaluate the regenerative potential of an injectable macroporous calcium phosphate cement (CaP) in combination with bone morphogenetic protein-2 (BMP-2) or fibroblast growth factor-2 (FGF-2)."( Periodontal regeneration using an injectable bone cement combined with BMP-2 or FGF-2.
Bronckers, AL; Jansen, JA; Meijer, GJ; Oortgiesen, DA; Walboomers, XF, 2014
)
0.4

Bioavailability

Phospholipid vesicles (liposomes) formed in pharmaceutically acceptable nonaqueous polar solvents such as propylene glycol are of interest in drug delivery. They can improve the bioavailability of drugs with poor aqueous solubility.

ExcerptReferenceRelevance
"Mechanisms and variations in the food-induced increase in the bioavailability of propranolol were assessed by single-dose (80 mg) studies in healthy volunteers who took the drug on an empty stomach, immediately after a protein-rich breakfast, and together with a carbohydrate-rich, protein-poor breakfast."( Mechanisms and variations in the food effect on propranolol bioavailability.
Liedholm, H; Melander, A; Wåhlin-Boll, E, 1990
)
0.28
" Chloramphenicol also was administered to older calves by IM and subcutaneous routes, with an apparent bioavailability of 50% to 60%."( Chloramphenicol and the neonatal calf.
Barto, PB; Burrows, GE; Craigmill, AL; Tyler, RD, 1984
)
0.27
" Hydrocortisone was slowly absorbed and did not reach a steady-state absorption rate during the experimental period."( Absorption and metabolism of hydrocortisone 21-butyrate, 21-hemisuccinate and hydrocortisone by skin of the rabbit ear during single-pass perfusion.
Bast, GE; Kampffmeyer, HG, 1994
)
0.29
"The cutaneous bioavailability of topical 2% minoxidil solution was verified in live hairless mice."( Drug and vehicle deposition from topical applications: localization of minoxidil within skin strata of the hairless mouse.
Ferry, JJ; Flynn, GL; Tsai, JC; Weiner, N, 1994
)
0.29
" However, SNAC itself was well absorbed across Caco-2 and its mechanism of permeation was determined."( Heparin absorption across the intestine: effects of sodium N-[8-(2-hydroxybenzoyl)amino]caprylate in rat in situ intestinal instillations and in Caco-2 monolayers.
Agarwal, R; Brayden, D; Creed, E; Leipold, H; Leone-Bay, A; O'Connell, A, 1997
)
0.3
" However, the bioavailability of ET is rather poor following oral administration."( Effect of cod-liver oil extract on the buccal permeation of ergotamine tartrate.
Loftsson, T; Nagai, T; Obata, Y; Takayama, K; Tsutsumi, K, 1998
)
0.3
", enhancement, irritation, drug binding) which have to be expected and could have altered the integrity of the stratum corneum and therewith topical bioavailability of the drug."( Effect of concentration and degree of saturation of topical fluocinonide formulations on in vitro membrane transport and in vivo availability on human skin.
Haigh, JM; Imanidis, G; Schwarb, FP; Smith, EW; Surber, C, 1999
)
0.3
" The absorption rate of TEN increased in parallel with increasing OA concentration, due to the alteration of the stratum corneum caused by this enhancer."( Combined effect of oleic acid and propylene glycol on the percutaneous penetration of tenoxicam and its retention in the skin.
Arellano, A; Larrucea, E; Santoyo, S; Ygartua, P, 2001
)
0.59
"Solubilizers are often used to enhance the bioavailability of drugs with poor aqueous solubility."( Common solubilizers to estimate the Caco-2 transport of poorly water-soluble drugs.
Kobayashi, S; Kondo, H; Takahashi, Y; Watanabe, T; Yasuda, T; Yokohama, S, 2002
)
0.31
" The corresponding mean absolute oral bioavailability figures were 36, 32, 39, 42 and 32% for ampicillin and 76, 74, 85, 73 and 74% for antipyrine, respectively."( Excipient effects on gastrointestinal transit and drug absorption in beagle dogs.
Basit, AW; Coffin, MD; Parsons, GE; Peters, EE; Schulze, JD; Staton, JS; Vickers, AW, 2005
)
0.33
" The bioavailability after oral administration of seocalcitol dissolved in medium chain triglyceride (MCT), long chain triglyceride (LCT), and a reference formulation containing propylene glycol (PG) was studied in vivo in rats."( Bioavailability of seocalcitol I: Relating solubility in biorelevant media with oral bioavailability in rats--effect of medium and long chain triglycerides.
Grove, M; Müllertz, A; Nielsen, JL; Pedersen, GP, 2005
)
0.52
" When the ceftriaxone/DCEA formulation was administered into a nonclosed segment of duodenum of rats, C(max) (the maximum drug concentration in plasma) and AUC (area under the curve) were significantly increased and its bioavailability was increased up to 70%."( Cationic analog of deoxycholate as an oral delivery carrier for ceftriaxone.
Byun, Y; Chae, SY; Kim, SK; Kumar, TS; Lee, DY; Lee, S; Park, K, 2005
)
0.33
" Indeed, the nature of E2's effects on conditioning may depend upon several factors, including, but not limited to, the task examined, route of E2 administration, bioavailability of E2 administered, and/or duration of E2 exposure."( Administration of estrogen to ovariectomized rats promotes conditioned place preference and produces moderate levels of estrogen in the nucleus accumbens.
Frye, CA; Rhodes, ME, 2006
)
0.33
"Oral administration of ceftriaxone associated with a bile acid-based new oral carrier, cholylethylenediamine, in 50% propylene glycol to rats at doses of 25 and 50 mg/kg of body weight resulted in a significant increase in intestinal absorption, as evidenced by 55% improvement in the bioavailability, whereas ceftriaxone alone showed a bioavailability of less than 1%."( Pharmacokinetics of a new, orally available ceftriaxone formulation in physical complexation with a cationic analogue of bile acid in rats.
Byun, Y; Chae, SY; Kim, SK; Lee, DY; Lee, S, 2006
)
0.54
"Atorvastatin is insoluble in aqueous solution and the bioavailability after oral administration is low."( Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin.
Shen, H; Zhong, M, 2006
)
0.33
" Furthermore, it had no significant effect on the absolute bioavailability (F(abs)): F(abs)=6."( Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats.
Agu, RU; Earles, DC; Hammell, DC; Paudel, KS; Stinchcomb, AL; Valiveti, S; Wermeling, DP, 2007
)
0.34
" Absorption of R-(+)-WIN 55,212-2 was rapid and bioavailability was significantly improved using methylated cyclodextrins and propylene glycol-based cosolvent."( Permeation of WIN 55,212-2, a potent cannabinoid receptor agonist, across human tracheo-bronchial tissue in vitro and rat nasal epithelium in vivo.
Agu, RU; Hayden, PJ; Klausner, M; Paudel, KS; Stinchcomb, AL; Valiveti, S, 2006
)
0.54
" Together, these results indicate that the bioavailability of ellagic acid can be improved by subcutaneous formulations administered as simple EA or EA nps."( Biodegradable in situ gelling system for subcutaneous administration of ellagic acid and ellagic acid loaded nanoparticles: evaluation of their antioxidant potential against cyclosporine induced nephrotoxicity in rats.
Italia, JL; Ravi Kumar, MN; Sharma, G; Sonaje, K; Tikoo, K, 2007
)
0.34
"The bioavailability of seocalcitol from two lipid-based formulations and a propylene glycol (PG) solution was studied in minipigs in the fasted and fed state."( Bioavailability of seocalcitol III. Administration of lipid-based formulations to minipigs in the fasted and fed state.
Grove, M; Müllertz, A; Nielsen, JL; Pedersen, GP, 2007
)
0.57
" In summary, tape-stripping experiments, with careful interpretation, can reveal details of a drug's bioavailability in the skin following topical application and may be used to probe the mechanism(s) by which certain excipients influence local drug delivery."( Effect of propylene glycol on ibuprofen absorption into human skin in vivo.
Guy, RH; Hadgraft, J; Herkenne, C; Kalia, YN; Naik, A, 2008
)
0.75
" Planned linear contrasts were performed to identify which formulations showed the highest bioavailability at 10, 30, 60 min and at all time points relative to DMSO alone."( In vivo pharmacokinetics and toxicity of a novel hydrophilic oral formulation of the potent non-nucleoside reverse transcriptase inhibitor compound N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea (HI-443).
Erbeck, D; Qazi, S; Tibbles, H; Uckun, FM; Venkatachalam, TK, 2007
)
0.34
" The results showed that tacrine could be directly transported into the brain from the nasal cavity and intranasal administration resulted in higher bioavailability of drug with reduced distribution into non-targeted tissues."( Nose-to-brain delivery of tacrine.
Jogani, VV; Mishra, AK; Mishra, P; Misra, AR; Shah, PJ, 2007
)
0.34
"The aim of this work was to improve the rectal bioavailability of quinine hydrochloride by designing thermosensitive and mucoadhesive gels intended for rectal delivery."( In vitro and in vivo characteristics of a thermogelling and bioadhesive delivery system intended for rectal administration of quinine in children.
Agnely, F; Besnard, M; Grossiord, JL; Kablan Brou, J; Koffi, AA; Ponchel, G, 2008
)
0.35
" The microemulsions displayed a 10-fold enhancement in bioavailability compared with plain insulin solution administered per oral in healthy rats."( Microemulsions for oral delivery of insulin: design, development and evaluation in streptozotocin induced diabetic rats.
Petrie, JR; Ravi Kumar, MN; Sattar, N; Sharma, G; van der Walle, CF; Wilson, K, 2010
)
0.36
" Optimised FFB SMEDDS formulations were then selected for in-vivo bioavailability study."( Characterisation of fenofibrate dissolution delivered by a self-microemulsifying drug-delivery system.
Chen, CH; Chen, ET; Ho, HO; Ke, WT; Sheu, MT; Wei, JD, 2010
)
0.36
" The objective of this study was to compare the bioavailability of test formulation with the reference formulation given intramuscularly in healthy volunteers."( Comparative bioavailability study of a new formulation of injection of 75 mg diclofenac sodium in 1 ml with the conventional injection of 75 mg diclofenac sodium given in 3 ml volume.
Jaiswal, V; Nivsarkar, M; Ojha, A; Padh, H; Patel, S; Shep, D, 2011
)
0.37
"A nonoral alternative such as transdermal system is desired to improve bioavailability and to maintain a constant and prolonged drug level with reduced frequency of dosing."( Influence of chemical permeation enhancers on transdermal permeation of alfuzosin: an investigation using response surface modeling.
Bindhani, A; Mallick, S; Pattnaik, S; Swain, K, 2011
)
0.37
" One hour later, single-pass intestinal perfusion experiments in jejunum and ileum and in vivo bioavailability studies were carried out to calculate the effective permeability coefficient and pharmacokinetic parameters, respectively."( Intestinal absorption and intestinal lymphatic transport of sirolimus from self-microemulsifying drug delivery systems assessed using the single-pass intestinal perfusion (SPIP) technique and a chylomicron flow blocking approach: linear correlation with o
Hu, L; Li, G; Si, L; Sun, M; Xue, K; Yang, X; Zhai, X, 2011
)
0.37
"To study the effect of β-cyclodextrin (βCD) inclusion complex on the bioavailability of clotrimazole from poloxamer-based suppository, formulations composed of P 188, propylene glycol and different molar ratio of clotrimazole-βCD inclusion complex were prepared."( Inclusion complex effect on the bioavailability of clotrimazole from poloxamer-based solid suppository.
Balakrishnan, P; Cho, HJ; Choi, HG; Kim, DD; Song, CK; Yang, SG; Yong, CS, 2012
)
0.57
"The developed CH-MEs are a viable alternative to conventional eye drops for its ability to enhance bioavailability through its longer precorneal residence time and its ability to sustain the release of the drug."( Mucoadhesive chitosan-coated cationic microemulsion of dexamethasone for ocular delivery: in vitro and in vivo evaluation.
Kant, S; Kesavan, K; Pandit, JK; Singh, PN, 2013
)
0.39
" In this study, propylene glycol was used as a linker to further compare the effect of the type of linker on the stability, permeability, affinity, and bioavailability of the prodrugs of OA."( Propylene glycol-linked amino acid/dipeptide diester prodrugs of oleanolic acid for PepT1-mediated transport: synthesis, intestinal permeability, and pharmacokinetics.
Cao, F; Fang, L; Gao, Y; Ping, Q; Wang, M, 2013
)
2.18
" The objective of this research work was to study the oral bioavailability and stability of a self-emulsifying drug delivery system (SEDDS) of amphotericin B (AmB)."( Oral bioavailability and stability study of a self-emulsifying drug delivery system (SEDDS) of amphotericin B.
Bajpai, M; Bhattacharyya, A, 2013
)
0.39
" The film formula of choice gave a significantly faster drug absorption rate and recorded a relative bioavailability of 204."( Fast-dissolving sublingual films of terbutaline sulfate: formulation and in vitro/in vivo evaluation.
El-Milligi, MF; Ibrahim, HK; Mohamed, MI; Sayed, S, 2013
)
0.39
"Phospholipid vesicles (liposomes) formed in pharmaceutically acceptable nonaqueous polar solvents such as propylene glycol are of interest in drug delivery because of their ability to improve the bioavailability of drugs with poor aqueous solubility."( Stabilization of distearoylphosphatidylcholine lamellar phases in propylene glycol using cholesterol.
Ara, N; Barlow, DJ; Harvey, RD; Heenan, RK; Lawrence, MJ; Quinn, PJ, 2013
)
0.84
" However, the oral bioavailability of these methoxyflavones has been shown to be low."( Transdermal permeation of Kaempferia parviflora methoxyflavones from isopropyl myristate-based vehicles.
Jaipakdee, N; Limpongsa, E; Sripanidkulchai, B; Tuntiyasawasdikul, S, 2014
)
0.4
"2-fold improved oral bioavailability of leuprolide oleate SMEDDS compared to a leuprolide acetate control solution."( In vivo evaluation of an oral self-microemulsifying drug delivery system (SMEDDS) for leuprorelin.
Bernkop-Schnürch, A; Hauptstein, S; Hintzen, F; Laffleur, F; Müller, C; Perera, G, 2014
)
0.4
"The aim of the present study was to prepare sublingual delivery systems for sildenafil and evaluate its relative bioavailability after sublingual administration in rabbits to attain a rapid onset of action with good efficacy at lower doses."( Rapid-Onset Sildenafil Sublingual Drug Delivery Systems: In Vitro Evaluation and In Vivo Pharmacokinetic Studies in Rabbits.
Chen, RN; Chou, PY; Ho, HO; Hsieh, CM; Sheu, MT, 2016
)
0.43
"Lipid-based self-emulsifying drug delivery systems (SEDDS) are commonly used for solubilizing and enhancing oral bioavailability of poorly water-soluble drugs."( Assessment of cell viability and permeation enhancement in presence of lipid-based self-emulsifying drug delivery systems using Caco-2 cell model: Polysorbate 80 as the surfactant.
Bu, P; Cheng, X; Dalrymple, D; Ji, Y; Narayanan, S; Serajuddin, AT, 2017
)
0.46
"In comparison to other published results, this study considered the extensive pre-systemic clearance of SV, which could significantly decrease its systemic and hepatic bioavailability if SV is delivered into the small intestine."( In vitro/in silico approach in the development of simvastatin-loaded self-microemulsifying drug delivery systems.
Ćetković, Z; Cvijić, S; Vasiljević, D, 2018
)
0.48
"The obtained results suggested that combined strategy for the improvement of SV bioavailability should comprise solubility enhancement and delayed drug release."( In vitro/in silico approach in the development of simvastatin-loaded self-microemulsifying drug delivery systems.
Ćetković, Z; Cvijić, S; Vasiljević, D, 2018
)
0.48
" The size of the droplets formed in the aerosol can vary and contributes to drug deposition and ultimate bioavailability in the lung."( The Effect of Electronic Cigarette User Modifications and E-liquid Adulteration on the Particle Size Profile of an Aerosolized Product.
Halquist, MS; Kosmider, L; Mulder, HA; Patterson, JL; Peace, MR; Poklis, A; Poklis, JL; Turner, JBM, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"The current investigation explores the possible mechanism of the microemulsion drug delivery system to improve the oral bioavailability of cinnamaldehyde (CA), an important food spice, from the perspective of the microemulsion-mucus system."( In vitro and in vivo evaluation of cinnamaldehyde Microemulsion-Mucus interaction.
Cai, Y; Chen, J; Chu, X; Dong, B; Wu, W, 2022
)
0.72

Dosage Studied

Cisapride mixed with propylene glycol and administered rectally at a dosage of 1 mg/kg is poorly and incompletely absorbed. The poloxamer-based solid suppository system with clotrimazole/P 188/propylene gly col was an effective rectal dosage form for the treatment of tumors.

ExcerptRelevanceReference
" The presence of PG generally enhanced the absorption of each drug, and the degree of enhancement appeared to be related to the percentage of PG in the dosing solution."( Propylene glycol as a vehicle for percutaneous absorption of therapeutic agents.
Bailey, DN,
)
1.57
"Two oral liquid dosage forms of acetazolamide have been developed."( Development of oral liquid dosage forms of acetazolamide.
Das Gupta, V; Parasrampuria, J, 1990
)
0.28
" Patients treated with simultaneous IV nitroglycerin and IV heparin must be monitored often to avoid inadequate anticoagulation, and heparin dosage should be decreased when stopping IV nitroglycerin therapy to avoid hemorrhage."( Heparin resistance induced by intravenous nitroglycerin. A word of caution when both drugs are used concomitantly.
Habbab, MA; Haft, JI, 1987
)
0.27
" Adequate monitoring of PTT and heparin dosage adjustment are thus required during combined heparin and NG administration."( [Inhibition of the heparin effect by nitroglycerin].
Lüderitz, B; Nitsch, J; Pizzulli, L, 1988
)
0.27
" The rate equation could be suitably used for optimizing the dosage schedule of a drug from the linear elimination pattern; in the present case this gave a Km value of 17."( Kinetics of propylene glycol elimination and metabolism in rat.
Amma, MK; Majumdar, S; Morshed, KM; Nagpaul, JP, 1988
)
0.65
" In the acute dosing experiment, metabolism of PG was the dominant disposition pathway, characterized by concentration-dependent metabolic clearance."( Pharmacokinetics of propylene glycol in the rabbit.
Sawchuk, RJ; Yu, DK, 1987
)
0.6
" After a minimum of 10 half-lives of maintenance dosing on a fixed regimen, the accumulation of propylene glycol differed significantly among individuals because of variability in apparent clearance."( Pharmacokinetics of propylene glycol in humans during multiple dosing regimens.
Elmquist, WF; Sawchuk, RJ; Yu, DK, 1985
)
0.81
" relative to acetaminophen dosing to inhibit CYP2E1 and CYP1A2, respectively."( Cytochrome P4502E1 inhibition by propylene glycol prevents acetaminophen (paracetamol) hepatotoxicity in mice without cytochrome P4501A2 inhibition.
Loft, S; Poulsen, HE; Roberts, DW; Thomsen, MS, 1995
)
0.57
" Cisapride mixed with propylene glycol and administered rectally at a dosage of 1 mg/kg is poorly and incompletely absorbed."( Pharmacokinetics of cisapride in horses after intravenous and rectal administration.
Bowman, KF; Cook, G; Papich, MG; Roberts, MC, 1997
)
0.61
" The plasma concentration of luteolin and its conjugates reached the highest level 15 min and 30 min after dosing with luteolin in propyleneglycol, respectively."( Intestinal absorption of luteolin and luteolin 7-O-beta-glucoside in rats and humans.
Furugori, M; Goda, T; Hara, Y; Kinae, N; Okada, H; Shimoi, K; Suzuki, M; Takase, S; Yamamoto, H, 1998
)
0.3
" The current studies may be applied to deliver MT transdermally using aqueous-based vehicles and to fabricate MT dosage forms."( Percutaneous absorption and model membrane variations of melatonin in aqueous-based propylene glycol and 2-hydroxypropyl-beta-cyclodextrin vehicles.
Ayres, JW; Cui, JH; Lee, BJ; Parrott, KA; Sack, RL, 1998
)
0.52
"Various monoolein-water systems containing tramadol HCl, a potent analgesic, were formulated to obtain sustained-release dosage forms which could be administered by subcutaneous, intramuscular or intrathecal injections."( In vitro/in vivo characterization of a tramadol HCl depot system composed of monoolein and water.
Fontaine, J; Malonne, H; Moës, A, 2000
)
0.31
"Three kinds of topical dosage forms of minoxidil (MXD), namely vesicles, double emulsions, and an inclusion complex with hydoxypropyl-beta-cyclodextrin (HP-beta-CD), were prepared."( Minoxidil-containing dosage forms: skin retention and after-rinsing hair-growth promotion.
Kim, JC; Lee, MH; Rang, MJ,
)
0.13
" Both studies showed a correlation between the amount of propylene glycol dosed on the skin and the amount of drug that had permeated."( Effect of finite doses of propylene glycol on enhancement of in vitro percutaneous permeation of loperamide hydrochloride.
Davis, AF; Hadgraft, J; Merly, C; Mirza, M; Trottet, L, 2004
)
0.87
"Eye drops are the most used dosage form by the ocular route, in spite of their low bioavailability."( New vehicle based on a microemulsion for topical ocular administration of dexamethasone.
da Silva-Cunha, A; Fialho, SL, 2004
)
0.32
" Taken together, the results suggest that a poloxamer gel system with 5-FU/P188/PG is an effective rectal dosage form for the treatment of both rectal and non-rectal cancers."( Poloxamer 188 and propylene glycol-based rectal suppository enhances anticancer effect of 5-fluorouracil in mice.
Choi, HG; Jeong, TC; Jin, CH; Kim, JA; Lee, YS; Oh, YK; Paek, SH; Park, BC; Xuan, JJ, 2006
)
0.67
" Thus, the poloxamer-based solid suppository system with clotrimazole/P 188/propylene glycol was an effective rectal dosage form for the treatment of tumors with alleviated adverse effects."( Enhanced anti-tumor activity and alleviated hepatotoxicity of clotrimazole-loaded suppository using poloxamer-propylene glycol gel.
Choi, HG; Kim, JA; Lee, MH; Oh, YK; Paek, SH; Woo, JS; Xuan, JJ; Yong, CS, 2006
)
0.78
" Stability of optimized patches was performed in natural human saliva showed that both drug and dosage forms were stable in human saliva."( Physicochemical characterization and evaluation of buccal adhesive patches containing propranolol hydrochloride.
Patel, JK; Patel, MM; Patel, VM; Prajapati, BG, 2006
)
0.33
"Film forming polymeric solutions may present an alternative to the common transdermal dosage forms such as patches or gels."( Delivery of ethinylestradiol from film forming polymeric solutions across human epidermis in vitro and in vivo in pigs.
Franke, P; Lehr, CM; Schaefer, UF; Zurdo Schroeder, I, 2007
)
0.34
" The present study illustrates an often mentioned beneficial effect of dosing lipid-based formulations; the reduced food effect on bioavailability."( Bioavailability of seocalcitol III. Administration of lipid-based formulations to minipigs in the fasted and fed state.
Grove, M; Müllertz, A; Nielsen, JL; Pedersen, GP, 2007
)
0.34
" The pharmacokinetics of 17 different novel oral formulations of HI-443 were compared in an attempt to identify the most suitable dosage form for clinical use in HIV-infected persons."( In vivo pharmacokinetics and toxicity of a novel hydrophilic oral formulation of the potent non-nucleoside reverse transcriptase inhibitor compound N'-[2-(2-thiophene)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea (HI-443).
Erbeck, D; Qazi, S; Tibbles, H; Uckun, FM; Venkatachalam, TK, 2007
)
0.34
"Xibornol is a lipophilic drug mainly used in Italy and Spain in spray dosage forms for the local treatment of infection and inflammation of the throat."( Liquid spray formulations of xibornol by using self-microemulsifying drug delivery systems.
Cirri, M; Mora, PC; Mura, P, 2007
)
0.34
" When cows were dosed with PG, the hepatic extraction of PG was between 0 and 10% depending on the plasma concentration of PG, explaining the slow decrease in arterial PG."( Ruminal and intermediary metabolism of propylene glycol in lactating Holstein cows.
Kristensen, NB; Raun, BM, 2007
)
0.61
" This selective localization of tacrine in the brain may be helpful in reducing dose, frequency of dosing and dose-dependent side effects, and may prove an interesting new approach in delivery of the drug to the brain for the treatment of Alzheimer's disease."( Nose-to-brain delivery of tacrine.
Jogani, VV; Mishra, AK; Mishra, P; Misra, AR; Shah, PJ, 2007
)
0.34
" Animals receiving PG had elevated insulin concentrations over the subsequent 90 min following dosing (P<0."( The effect of feeding propylene glycol to dairy cows during the early postpartum period on follicular dynamics and on metabolic parameters related to fertility.
Boland, MP; Duffy, P; Griffin, W; Kenny, DA; Lonergan, P; Mulligan, FJ; Quinn, KM; Rizos, D; Roche, JF, 2008
)
0.66
" The influence of solubilizers on the aqueous solubility of the itraconazole, ketoconazole and miconazole was investigated in order to enhance their solubility for a possible parenteral dosage form."( Aqueous solvent system for the solubilization of azole compounds.
Antal, I; Klebovich, I; Kovács, K; Ludányi, K; Stampf, G, 2009
)
0.35
"The development of a practical and pharmaceutically acceptable parenteral dosage form of 1 is described."( Parenteral formulation and thermal degradation pathways of a potent rebeccamycin based indolocarbazole topoisomerase I inhibitor.
Breslin, D; Karki, SB; Kitada, H; Minagawa, W; Nomoto, T; Qin, XZ; Sato, Y, 2010
)
0.36
" In these teratology studies, pregnant females were dosed during the period of organogenesis, followed by an assessment of fetal external, visceral, and skeletal development."( Assessment of hydroxypropyl methylcellulose, propylene glycol, polysorbate 80, and hydroxypropyl-β-cyclodextrin for use in developmental and reproductive toxicology studies.
Enright, BP; Kopytek, SJ; McIntyre, BS; Thackaberry, EA; Treinen, KA, 2010
)
0.62
" Hence, such formulations of previously well established molecules provide a new direction towards developing better and convenient dosing alternatives."( Comparative bioavailability study of a new formulation of injection of 75 mg diclofenac sodium in 1 ml with the conventional injection of 75 mg diclofenac sodium given in 3 ml volume.
Jaiswal, V; Nivsarkar, M; Ojha, A; Padh, H; Patel, S; Shep, D, 2011
)
0.37
"The carried out studies allowed to propose composition of stomatological dressing makes opportunity to ensure preferable physiochemicals features for dosage forms."( [The effect of the composition of stomatological dressings on Carbopol 971P and methylocelullose base on pharmaceutical availability of metronidazole].
Kida, D; Pluta, J, 2011
)
0.37
"The aim of this study was to investigate the use of liquisolid technique in improving the dissolution of glyburide in a solid dosage form."( Influence of formulation parameters on dissolution rate enhancement of glyburide using liquisolid technique.
Gaikwad, NB; Gowthamarajan, K; Prakash, D; Singare, DS; Singh, SK; Srinivasan, KK, 2012
)
0.38
" The final model shows that for commonly used dosing regimens, the population mean PG peak and trough concentrations range between 33-144 and 28-218 mg l(-1) (peak) and 19-109 and 6-112 mg l(-1) (trough) for paracetamol and phenobarbital formulations, respectively, depending on birth weight and age of the neonates."( Developmental pharmacokinetics of propylene glycol in preterm and term neonates.
Allegaert, K; Danhof, M; De Cock, RF; de Hoon, J; Knibbe, CA; Kulo, A; Verbesselt, R, 2013
)
0.67
" All of these results indicate that the main advantages of PEHFL over conventional dosage forms are the ability to enhance the vaginal mucosa permeability of MT, spread uniformly in vaginal canal especially the highly folded epithelial surfaces, prolong the residence time at the site of administration and induce MT delayed release."( Post-expansile hydrogel foam aerosol of PG-liposomes: a novel delivery system for vaginal drug delivery applications.
Bao-Hua, H; Chun-Feng, Z; Li, WZ; Peng, K; Xiao-Ning, W; Yang, LB; Zhao, N; Zhou, YQ, 2012
)
0.38
"7 times, respectively, with reference to the oral dosage form."( Development of matrix-type transdermal delivery of lornoxicam: in vitro evaluation and pharmacodynamic and pharmacokinetic studies in albino rats.
Baviskar, DT; Jain, DJ; Parik, VB,
)
0.13
" In particular, poor solubility is one of the challenges for development of a parenteral dosage form."( Pharmaceutical development of a parenteral formulation of conivaptan hydrochloride.
Ban, K; Namiki, N; Sako, K; Sonohara, R; Uchida, S; Yoshida, M,
)
0.13
"Liquisolid technique is a new approach to formulate sustained release dosage forms."( Effect of solvent type on retardation properties of diltiazem HCl form liquisolid tablets.
Adibkia, K; Barzegar-Jalali, M; Javadzadeh, Y; Shokri, J; Solduzian, M, 2014
)
0.4
" IBU solutions with and without propylene glycol (PG), polyethylene glycol 200 (PEG 200), and/or octisalate (OS) were dosed onto the forearm of participants."( The effect of formulation excipients on the penetration and lateral diffusion of ibuprofen on and within the stratum corneum following topical application to humans.
Finnin, BC; Gee, CM; Nicolazzo, JA; Watkinson, AC, 2014
)
0.69
"The quest for achieving optimal therapeutic outcomes in pediatric patients has evaded the healthcare professionals for long and often lack of child specific dosage forms and the associated events that follow with it have been considered to be major contributor towards suboptimal outcomes."( Issues impacting therapeutic outcomes in pediatric patients: an overview.
Goindi, S; Kalra, A, 2014
)
0.4
" Vehicles were dosed orally once daily to HanWistar rats for a minimum of 28 days and a wide range of toxicological parameters were assessed."( Safety data on 19 vehicles for use in 1 month oral rodent pre-clinical studies: administration of hydroxypropyl-ß-cyclodextrin causes renal toxicity.
Burdett, L; Cotton, P; Finney, R; Garner, C; Hargreaves, A; Harris, J; Healing, G; Kirk, S; Pivette, P; Schramm, C; Sulemann, T, 2016
)
0.43
" For sublingual application, sildenafil and its citrate were formulated in 2 different dosage forms: the first was a sublingual spray consisting of sildenafil in 2 microemulsion systems, oleic acid or propylene glycol (PG), and the second was sublingual tablets prepared with various granulated sublingual sprays adsorbed onto a silicate adsorbant (Florite(®) R), binders (Cyclocel(®) or EMDEX(®)), and disintegrants (Ac-Di-Sol(®) or Kollidon(®) CL)."( Rapid-Onset Sildenafil Sublingual Drug Delivery Systems: In Vitro Evaluation and In Vivo Pharmacokinetic Studies in Rabbits.
Chen, RN; Chou, PY; Ho, HO; Hsieh, CM; Sheu, MT, 2016
)
0.62
" At time of calving, nine ruminally cannulated Holstein cows were randomly assigned to ruminal dosing of 500 g/d tap water (CON, n = 4) or 500 g/d PG (PPG, n = 5)."( Effect of postpartum propylene glycol allocation to over-conditioned Holstein cows on concentrations of milk metabolites.
Bjerre-Harpøth, V; Larsen, M; Larsen, T; Storm, AC; Vestergaard, M, 2016
)
0.75
"Many drugs are unavailable in suitable oral paediatric dosage forms, and pharmacists often have to compound drugs to provide paediatric patients with an acceptable formulation in the right dose."( Formulating a poorly water soluble drug into an oral solution suitable for paediatric patients; lorazepam as a model drug.
Eckhardt, M; Hanff, LM; Koch, BC; Postma, DJ; Smeets, OS; van der Velde, I; van der Vossen, AC; Vermes, A; Vulto, AG, 2017
)
0.46
"There is extensive literature on in vivo studies with cordycepin, but these studies were generally conducted without validation of the various formulations, especially in terms of the solubility of cordycepin in the dosing vehicles used."( Development of Cordycepin Formulations for Preclinical and Clinical Studies.
Adrower, C; de Moor, CH; Fischer, PM; Gershkovich, P; Lee, JB; Qin, C, 2017
)
0.46
" The developed SV-specific PBPK model could potentially be used to assess the influence of formulation factors on drug absorption and disposition when developing SV oral dosage forms."( In vitro/in silico approach in the development of simvastatin-loaded self-microemulsifying drug delivery systems.
Ćetković, Z; Cvijić, S; Vasiljević, D, 2018
)
0.48
" Although PG is generally considered safe, the dosage can exceed safety thresholds in neonates."( Spectroscopic detection of brain propylene glycol in neonates: Effects of different pharmaceutical formulations of phenobarbital.
Pouwels, PJW; van de Lagemaat, M; van de Pol, LA; Witjes, BCM; Zonnenberg, IA, 2019
)
0.8
"Solid phase interactions are often the reason for incompatibilities in solid dosage forms."( Drug-plasticizer interactions causing solid state transitions of rifaximin.
Höfler, K; Littringer, E; Pichler, A; Scheler, S, 2022
)
0.72
" According to the dose-response bioassays and room size chamber testing, the highest larvicidal, pupicidal and adulticidal activities were observed with D2, followed by D1 and negative control."( Effect of short-chain alcohols on the physicochemical properties of d-phenothrin emulsions and their insecticidal activity against Aedes aegypti.
Hasan, ZAA; Mohsin, SMN, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (234 Items)

ItemProcessFrequency
Snackscore-ingredient217
Sweet snackscore-ingredient167
Biscuits and cakescore-ingredient130
Cooking helperscore-ingredient98
Cakescore-ingredient97
Dessertscore-ingredient72
Frozen foodscore-ingredient62
Sweetenerscore-ingredient57
Simple syrupscore-ingredient56
Syrupscore-ingredient56
Condimentscore-ingredient54
Plant-based foods and beveragescore-ingredient53
Frozen dessertscore-ingredient52
Beveragescore-ingredient46
Open Beauty Factscore-ingredient44
Groceriescore-ingredient43
en:open-beauty-factscore-ingredient42
Meatscore-ingredient39
Meats and their productscore-ingredient39
Confectioneriescore-ingredient37
Plant-based foodscore-ingredient34
Non food productscore-ingredient34
Food additivescore-ingredient33
Pastry helperscore-ingredient29
Prepared meatscore-ingredient29
Cake mixescore-ingredient26
Dessert mixescore-ingredient26
Baking Mixescore-ingredient26
Biscuitscore-ingredient26
Saucescore-ingredient24
Flavorscore-ingredient20
Chocolate candiescore-ingredient19
Cocoa and its productscore-ingredient19
Baking decorationscore-ingredient18
Cereals and potatoescore-ingredient17
Salted snackscore-ingredient14
Sausagescore-ingredient12
Creamercore-ingredient11
Dairy substitutescore-ingredient11
Food coloringscore-ingredient11
Breadscore-ingredient10
Dairiescore-ingredient10
Spicescore-ingredient10
Milk substitutescore-ingredient10
Ice creams and sorbetscore-ingredient10
Pastriescore-ingredient10
Ice creamscore-ingredient9
Alcoholic beveragescore-ingredient9
Additifs alimentairescore-ingredient9
Vanilla extractcore-ingredient8
fr:Arômes pâtisseriecore-ingredient8
Vanillacore-ingredient8
Plant-based beveragescore-ingredient8
Arômescore-ingredient8
Cereals and their productscore-ingredient7
Frozen meatscore-ingredient7
Non alimentairecore-ingredient7
Iced teascore-ingredient6
Tea-based beveragescore-ingredient6
Sodascore-ingredient6
Carbonated drinkscore-ingredient6
Cheesescore-ingredient6
Fermented milk productscore-ingredient6
Fermented foodscore-ingredient6
Arômes pâtisseriecore-ingredient6
Dipscore-ingredient5
Pie doughcore-ingredient5
Salad dressingscore-ingredient5
Chocolatescore-ingredient4
Dried products to be rehydratedcore-ingredient4
Dried productscore-ingredient4
Biscuits et gâteauxcore-ingredient4
sucréscore-ingredient4
Artificially sweetened beveragescore-ingredient4
Non-Food-Produktecore-ingredient4
Assorted chocolatescore-ingredient3
Dehydrated beveragescore-ingredient3
Gâteauxcore-ingredient3
Flavour enhancerscore-ingredient3
Extrait de vanillecore-ingredient3
Vanillecore-ingredient3
Epicescore-ingredient3
Aliments d'origine végétalecore-ingredient3
Aliments et boissons à base de végétauxcore-ingredient3
en:groceriescore-ingredient3
Canned foodscore-ingredient2
Ice cream barscore-ingredient2
Mealscore-ingredient2
Special breadscore-ingredient2
Rice puddingscore-ingredient2
Puddingscore-ingredient2
Milkscore-ingredient2
Cottage cheesescore-ingredient2
Fresh cheesescore-ingredient2
Seafoodcore-ingredient2
Energy drinkscore-ingredient2
Nuts and their productscore-ingredient2
Dietary supplementscore-ingredient2
Plant-based spreadscore-ingredient2
Spreadscore-ingredient2
Arôme de vanillecore-ingredient2
Cosmétiquescore-ingredient2
Productos no alimenticioscore-ingredient2
Hot saucescore-ingredient1
Creamscore-ingredient1
Fruit-based beveragescore-ingredient1
Compound dairy creamscore-ingredient1
Iced teas with lemonadecore-ingredient1
Lemonadecore-ingredient1
Canned common beanscore-ingredient1
Canned legumescore-ingredient1
Canned plant-based foodscore-ingredient1
Legumescore-ingredient1
Legumes and their productscore-ingredient1
Sliced baconcore-ingredient1
Baconcore-ingredient1
Porkcore-ingredient1
Pork and its productscore-ingredient1
Stewscore-ingredient1
Thousand island dressingcore-ingredient1
Hamburger bunscore-ingredient1
Spice Mixcore-ingredient1
Milk chocolatescore-ingredient1
Pancakescore-ingredient1
Crêpes and galettescore-ingredient1
Lemon flavored iced teascore-ingredient1
Corn chipscore-ingredient1
Crispscore-ingredient1
Chips and friescore-ingredient1
Appetizerscore-ingredient1
Salty snackscore-ingredient1
Canned meatscore-ingredient1
Doughnutscore-ingredient1
snack cakecore-ingredient1
en:cooking-helperscore-ingredient1
Marble cakescore-ingredient1
Frozen seafoodcore-ingredient1
Saucissescore-ingredient1
Charcuteriescore-ingredient1
Viandescore-ingredient1
Viandes et dérivéscore-ingredient1
Pork sausagescore-ingredient1
Water enhancercore-ingredient1
Toppingscore-ingredient1
Almondscore-ingredient1
Nutscore-ingredient1
Chocolate muffinscore-ingredient1
Chocolate cakescore-ingredient1
Muffinscore-ingredient1
Frozen yogurtscore-ingredient1
en:food-additivescore-ingredient1
en:Instant noodle soupscore-ingredient1
en:Instant noodlescore-ingredient1
en:Noodlescore-ingredient1
en:Dried products to be rehydratedcore-ingredient1
en:Pastascore-ingredient1
en:Dried productscore-ingredient1
en:Cereals and their productscore-ingredient1
en:Cereals and potatoescore-ingredient1
en:Plant-based foodscore-ingredient1
en:Plant-based foods and beveragescore-ingredient1
Instant noodlescore-ingredient1
Noodlescore-ingredient1
Pastascore-ingredient1
Vegetable fatscore-ingredient1
Fatscore-ingredient1
Open Products Factscore-ingredient1
Poultriescore-ingredient1
Pitascore-ingredient1
Flatbreadscore-ingredient1
Sorbetscore-ingredient1
Jamscore-ingredient1
Fruit and vegetable preservescore-ingredient1
Sweet spreadscore-ingredient1
Breakfastscore-ingredient1
Coconut Macaroonscore-ingredient1
Mahmoudcore-ingredient1
Badycore-ingredient1
en:dietary-supplementscore-ingredient1
Ice popscore-ingredient1
Sugarscore-ingredient1
Mexican Dinner Mixescore-ingredient1
Caffinecore-ingredient1
Throat lozengescore-ingredient1
Artificial Flavorcore-ingredient1
Almond butterscore-ingredient1
Nut butterscore-ingredient1
Oilseed pureescore-ingredient1
fr:Cire de Coiffagecore-ingredient1
Air freshenercore-ingredient1
Candiescore-ingredient1
fr:Arôme de vanillecore-ingredient1
fr:aromes-patisseriecore-ingredient1
Substitut nicotiniquecore-ingredient1
de:Deocore-ingredient1
Gâteau basque à la crème pâtissièrecore-ingredient1
Pâtisseriescore-ingredient1
Déodorantcore-ingredient1
Chocolate dessertscore-ingredient1
en:deodorantscore-ingredient1
en:toothpastecore-ingredient1
Protein powderscore-ingredient1
Bodybuilding supplementscore-ingredient1
de:Zahnpastacore-ingredient1
en:Non food productscore-ingredient1
Facial washcore-ingredient1
Black peppercornscore-ingredient1
Black pepperscore-ingredient1
Peppercornscore-ingredient1
Pepperscore-ingredient1
Popcorncore-ingredient1
Vanilla alcoholic extractcore-ingredient1
whole wheat tortilla wrapcore-ingredient1
Antibactériencore-ingredient1
Skin carecore-ingredient1
Face care gelcore-ingredient1
Wafflescore-ingredient1
nl:Haarproductencore-ingredient1
Colorants alimentairescore-ingredient1
en:candiescore-ingredient1
acid hialuroniccore-ingredient1
Vücut spreyicore-ingredient1
Hygiène beautécore-ingredient1
Fish fingerscore-ingredient1
Breaded fishcore-ingredient1
Breaded productscore-ingredient1
Fish preparationscore-ingredient1
Fishescore-ingredient1
Mouthwashcore-ingredient1
Bifidus yogurtscore-ingredient1
Vanilacore-ingredient1
en:skinvarecore-ingredient1
Ibuprofen soft gel capsulescore-ingredient1
Flavouring Extractcore-ingredient1

Roles (4)

RoleDescription
protic solventA polar solvent that is capable of acting as a hydron (proton) donor.
allergenA chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
propane-1,2-diols
glycolA diol in which the two hydroxy groups are on different carbon atoms, usually but not necessarily adjacent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (6)

PathwayProteinsCompounds
Pyruvate Metabolism2139
Leigh Syndrome2139
Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency)2139
Pyruvate Dehydrogenase Complex Deficiency2139
Primary Hyperoxaluria II, PH22139
Pyruvate Kinase Deficiency2139

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency5.01190.004023.8416100.0000AID485290
GLI family zinc finger 3Homo sapiens (human)Potency2.02740.000714.592883.7951AID1259369; AID1259392
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency29.51970.001022.650876.6163AID1224838
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency35.08420.003041.611522,387.1992AID1159555
estrogen nuclear receptor alphaHomo sapiens (human)Potency25.62410.000229.305416,493.5996AID743069; AID743075; AID743079
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
Cellular tumor antigen p53Homo sapiens (human)Potency2.43370.002319.595674.0614AID651631
Nuclear receptor ROR-gammaHomo sapiens (human)Potency7.49780.026622.448266.8242AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (134)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (38)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (19)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1134606Et2O-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID490179Toxicity in rat assessed as time spent on rotarod at 0.5 mL, ip by rotarod test2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and antipsychotic and anticonvulsant activity of some new substituted oxa/thiadiazolylazetidinonyl/thiazolidinonylcarbazoles.
AID167125Eye irritation potential accessed using Draize in vivo rabbit eye irritation test2003Journal of medicinal chemistry, Apr-10, Volume: 46, Issue:8
Mapping property distributions of molecular surfaces: algorithm and evaluation of a novel 3D quantitative structure-activity relationship technique.
AID1394711Cytotoxicity against NHDF assessed as reduction in cell viability up to 200 uM after 5 days by CellTiter-Glo assay2018European journal of medicinal chemistry, Apr-25, Volume: 150Structure-activity relationship studies of ultra-short peptides with potent activities against fluconazole-resistant Candida albicans.
AID490176Anticonvulsant activity in rat assessed as protection against maximal electric shock-induced seizures at 0.5 mL, ip2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and antipsychotic and anticonvulsant activity of some new substituted oxa/thiadiazolylazetidinonyl/thiazolidinonylcarbazoles.
AID477214Anticonvulsant activity in Charles foster rat assessed as protection against maximal electroshock-induced seizures at 30 mg/kg, ip administered 1 hr before electroshock challenge2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Synthesis and evaluation of some new substituted benzothiazepine and benzoxazepine derivatives as anticonvulsant agents.
AID1659751Agonist activity at TRPA1 (unknown origin) at 1000 uM relative to AITC2020Bioorganic & medicinal chemistry letters, 06-01, Volume: 30, Issue:11
Identification of a new class of non-electrophilic TRPA1 agonists by a structure-based virtual screening approach.
AID1134605Oil-water partition coefficient, log P of the compound1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Hydrogen-bonding parameter and its significance in quantitative structure--activity studies.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,051)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990307 (14.97)18.7374
1990's297 (14.48)18.2507
2000's557 (27.16)29.6817
2010's671 (32.72)24.3611
2020's219 (10.68)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 70.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index70.93 (24.57)
Research Supply Index7.74 (2.92)
Research Growth Index4.74 (4.65)
Search Engine Demand Index194.90 (26.88)
Search Engine Supply Index3.07 (0.95)

This Compound (70.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials97 (4.42%)5.53%
Reviews81 (3.69%)6.00%
Case Studies107 (4.87%)4.05%
Observational2 (0.09%)0.25%
Other1,908 (86.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]